Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During...
Saved in:
Published in | Saudi pharmaceutical journal Vol. 30; no. 12; pp. 1725 - 1735 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Saudi Arabia
Elsevier B.V
01.12.2022
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. The aim of this study was to investigate VAERS patterns, reported AEFI, vaccines, and impact of different pandemics since its inception.
This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365.
There were 1,396,280 domestic and 346,210 non-domestic reports during 1990–2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52 % and 70.33 %), in addition a notable change in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00 % and 4.08 %), ER or doctor visits (13.37 % and 2.27 %), hospitalizations (5.84 % and 27.78 %), lethal threat (1.42 % and 4.38 %), and disabilities (1.4 % and 7.96 %). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines.
The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate. |
---|---|
AbstractList | Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. The aim of this study was to investigate VAERS patterns, reported AEFI, vaccines, and impact of different pandemics since its inception.
This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365.
There were 1,396,280 domestic and 346,210 non-domestic reports during 1990-2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52 % and 70.33 %), in addition a notable change in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00 % and 4.08 %), ER or doctor visits (13.37 % and 2.27 %), hospitalizations (5.84 % and 27.78 %), lethal threat (1.42 % and 4.38 %), and disabilities (1.4 % and 7.96 %). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines.
The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate. Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. The aim of this study was to investigate VAERS patterns, reported AEFI, vaccines, and impact of different pandemics since its inception.BackgroundVaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. The aim of this study was to investigate VAERS patterns, reported AEFI, vaccines, and impact of different pandemics since its inception.This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365.MethodsThis was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365.There were 1,396,280 domestic and 346,210 non-domestic reports during 1990-2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52 % and 70.33 %), in addition a notable change in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00 % and 4.08 %), ER or doctor visits (13.37 % and 2.27 %), hospitalizations (5.84 % and 27.78 %), lethal threat (1.42 % and 4.38 %), and disabilities (1.4 % and 7.96 %). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines.ResultsThere were 1,396,280 domestic and 346,210 non-domestic reports during 1990-2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52 % and 70.33 %), in addition a notable change in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00 % and 4.08 %), ER or doctor visits (13.37 % and 2.27 %), hospitalizations (5.84 % and 27.78 %), lethal threat (1.42 % and 4.38 %), and disabilities (1.4 % and 7.96 %). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines.The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate.ConclusionsThe large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate. Background: Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting post-marketing Adverse events following immunizations (AEFIs) reports to monitor the vaccine safety and to mitigate the risks from vaccines. During the coronavirus diseases 2019 (COVID-19) pandemic, VAERS got more attention as its important role in monitoring the safety of the vaccines. The aim of this study was to investigate VAERS patterns, reported AEFI, vaccines, and impact of different pandemics since its inception. Methods: This was an observational study using VARES data from 2/7/1990 to 12/11/2021. Patterns of reports over years were first described, followed by a comparison of reports statistics per year. Furthermore, a comparison of incidents (death, ER visits, etc.) statistics over years, in addition to statistics of each vaccine were calculated. Moreover, each incident's statistics for each vaccine were calculated and top vaccines were reported. All analyses were conducted using R (Version 1.4.1717) and Excel for Microsoft 365. Results: There were 1,396,280 domestic and 346,210 non-domestic reports during 1990–2021, including 228 vaccines. For both domestic and non-domestic reports, year of 2021 had the highest reporting rate (48.52 % and 70.33 %), in addition a notable change in AEFIs patterns were recorded during 1991, 1998, 2000, 2006, 2009, 2011, and 2017. AEFIs were as follow: deaths (1.00 % and 4.08 %), ER or doctor visits (13.37 % and 2.27 %), hospitalizations (5.84 % and 27.78 %), lethal threat (1.42 % and 4.38 %), and disabilities (1.4 % and 7.96 %). Pyrexia was the top reported symptom during the past 31 years, except for 2021 where headache was the top one. COVID-19 vaccines namely Moderna, Pfizer-Biontech, and Janssen were the top 3 reported vaccines with headache, pyrexia, and fatigue as the top associated AEFIs. Followed by Zoster, Seasonal Influenza, Pneumococcal, and Human papillomavirus vaccines. Conclusions: The large data available in VARES make it a useful tool for detecting and monitoring vaccine AEFIs. However, its usability relies on understating the limitations of this surveillance system, the impact of governmental regulations, availability of vaccines, and public health recommendations on the reporting rate. |
Author | Almadani, Ohoud A. Alshammari, Thamir M. |
Author_xml | – sequence: 1 givenname: Ohoud A. orcidid: 0000-0002-6246-0841 surname: Almadani fullname: Almadani, Ohoud A. organization: Saudi Food and Drug Authority, Riyadh, Saudi Arabia – sequence: 2 givenname: Thamir M. orcidid: 0000-0002-5630-2468 surname: Alshammari fullname: Alshammari, Thamir M. email: thamer.alshammary@gmail.com organization: Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36601511$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc9u1DAQxi1URLeFF-CAfCyHXfwnTmKEkKpqgUqVkKDq1Zo4k8WrJA52NtLeeA1ejyfBIaWiFy72aOabn8fznZGT3vdIyEvONpzx_M1-s49D3AgmREpsGONPyEoILtdFVqgTsuKS63VSZqfkLMY9Y0IpLZ-RU5nnjCvOV8TdgbWuRwr1hCEixQn7kQYcfBhdv6PxGEfs6MXd5fbL19dv6XaC9gCj8z31DZWcHhFCnOOlJ1LoazqkAztn468fP6nrBrDjc_K0gTbii_v7nNx-2N5efVrffP54fXV5s7ZZIcZ1mSFwKLRqOLNQQJZm1baqqhKY1lo00ChRpSoyJVFmFSIHkJW0TBeg5Tm5XrC1h70ZgusgHI0HZ_4kfNgZSD-zLRqoecNKnTHVsEylqCgypVXOkGtW2yyx3i-s4VB1WNu0mQDtI-jjSu--mZ2fjC6Z0oVMgIt7QPDfDxhH07losW2hR3-IRhQ55yUT5SwVi9QGH2PA5uEZzsxst9mb2W4z2z3nkt2p6dW_Az60_PU3Cd4tAkwbnxwGE63D3mLtAtox7cT9j_8b4Om-2g |
Cites_doi | 10.1212/WNL.86.16_supplement.P1.147 10.1016/j.vaccine.2018.08.085 10.1017/S0950268806007096 10.1007/s10552-021-01430-4 10.1097/00006454-200404000-00002 10.1057/palgrave.jphp.3190016 10.12688/f1000research.22600.2 10.1037/e601292007-001 10.1016/j.puhe.2015.11.010 10.1542/peds.93.5.747 10.4161/hv.24657 10.1136/bmj.n1435 10.1016/j.vaccine.2011.10.076 10.1038/s41541-019-0132-6 10.1016/j.vaccine.2012.05.039 10.1186/s12911-019-0818-8 10.1136/bmj.c7452 10.1038/s41467-022-28068-3 10.2471/BLT.07.048025 10.1038/s41591-021-01556-7 10.1016/j.vaccine.2017.03.035 10.1056/NEJMoa2110737 10.1016/j.idc.2017.11.005 10.2807/1560-7917.ES.2018.23.17.17-00468 10.3389/fphar.2019.00948 10.1016/j.vaccine.2015.07.035 10.15585/mmwr.rr7005a1 10.1016/j.mpdhp.2016.06.005 10.3390/vaccines8010101 10.15585/mmwr.mm7031e1 10.1056/NEJMoa2110475 10.1093/cid/ciq115 10.4103/0019-5545.82529 |
ContentType | Journal Article |
Copyright | 2022 The Author(s) 2022 The Author(s). 2022 The Author(s) 2022 |
Copyright_xml | – notice: 2022 The Author(s) – notice: 2022 The Author(s). – notice: 2022 The Author(s) 2022 |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1016/j.jsps.2022.10.001 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2213-7475 |
EndPage | 1735 |
ExternalDocumentID | oai_doaj_org_article_ad1f089405f04508977459560e190dc4 10_1016_j_jsps_2022_10_001 36601511 S1319016422002493 |
Genre | Journal Article |
GroupedDBID | --- --K 0R~ 0SF 123 1B1 4.4 457 53G 5VS 6I. 71M AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAQFI AAXUO ABMAC ACGFO ACGFS ADBBV ADEZE ADMUD AENEX AEXQZ AFTJW AGHFR AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV DIK DU5 E3Z EBS EJD EP3 FDB FEDTE FNPLU GROUPED_DOAJ GX1 HH5 HVGLF HYE HZ~ IPNFZ IXB KQ8 NCXOZ O-L O9- OK1 OZT P2P RIG ROL RPM SES SSZ TR2 XH2 ~S- ADVLN AFJKZ AKRWK NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c472t-84ea1a795f10ca7a43669cbbb8a09992faf52b5f1e053e34bee1aa3b3c097a93 |
IEDL.DBID | RPM |
ISSN | 1319-0164 |
IngestDate | Fri Oct 04 13:02:04 EDT 2024 Tue Sep 17 21:30:23 EDT 2024 Tue Sep 10 16:30:53 EDT 2024 Wed Oct 09 16:51:42 EDT 2024 Sun Oct 13 09:35:02 EDT 2024 Fri Feb 23 02:38:41 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | COVID-19 VAERS AEFI Vaccines AESI Surveillance |
Language | English |
License | This is an open access article under the CC BY license. 2022 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c472t-84ea1a795f10ca7a43669cbbb8a09992faf52b5f1e053e34bee1aa3b3c097a93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6246-0841 0000-0002-5630-2468 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805973/ |
PMID | 36601511 |
PQID | 2761180283 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ad1f089405f04508977459560e190dc4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9805973 proquest_miscellaneous_2761180283 crossref_primary_10_1016_j_jsps_2022_10_001 pubmed_primary_36601511 elsevier_sciencedirect_doi_10_1016_j_jsps_2022_10_001 |
PublicationCentury | 2000 |
PublicationDate | 2022-12-01 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Saudi Arabia |
PublicationPlace_xml | – name: Saudi Arabia |
PublicationTitle | Saudi pharmaceutical journal |
PublicationTitleAlternate | Saudi Pharm J |
PublicationYear | 2022 |
Publisher | Elsevier B.V Elsevier |
Publisher_xml | – name: Elsevier B.V – name: Elsevier |
References | Milstien (b0200) 2004; 25 (accessed 2.6.22). VAERS, 1990. VAERS - About Us [WWW Document]. URL Zhao, Murphy, Jacques-Carroll (b0280) 2011; 30 Food and Drug Authority, 2009. Gardasil Vaccine Safety | FDA [WWW Document]. URL World Health Organization (WHO), 2014. Global manual on surveillance of adverse events following immunization. Geneva. Alguacil-Ramos, Muelas-Tirado, Garrigues-Pelufo, Portero-Alonso, Diez-Domingo, Pastor-Villalba, Lluch-Rodrigo (b0005) 2016; 135 Food and Drug Authority (FDA), 2001. Vaccine and Related Biological Product Guidances | FDA [WWW Document]. URL Hervé, Laupèze, del Giudice, Didierlaurent, Tavares Da Silva (b0145) 2019; 4 Kochhar, Excler, Bok, Gurwith, McNeil, Seligman, Khuri-Bulos, Klug, Laderoute, Robertson, Singh, Chen (b0160) 2019; 37 Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., Bettinger, J.A., 2013. Human Vaccines & Immunotherapeutics Vaccine hesitancy An overview 1763–1773. Schillie, S., Murphy, T.V., Sawyer, M., Ly, K., Hughes, E., Jiles, R., de Perio, M.A., Reilly, M., Byrd, K., Ward, J.W., 2013. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 62. Food and Drug Authority (FDA), 2020. Emergency Use Authorization for Vaccines Explained | FDA [WWW Document]. URL World Health Organization, 2019. Immunization [WWW Document]. URL Lai, Huang, Chui, Wan, Li, Wong, Chan, Ma, Lum, Leung, Luo, Chan, Wong (b0165) 2022; 13 Nigrovic, Thompson (b0205) 2007; 135 Mentzer, Oberle, Keller-Stanislawski (b0195) 2018; 23 FDA, CBER, 2021. Contains Nonbinding Recommendations Emergency Use Authorization for Vaccines to Prevent COVID-19 Guidance for Industry Preface Public Comment. Hause, A.M., Gee, J., Baggs, J., Abara, W.E., Marquez, P., Thompson, D., Su, J.R., Licata, C., Rosenblum, H.G., Myers, T.R., Shimabukuro, T.T., Shay, D.K., 2020. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. Centers for Disease Control and Prevention, 2021. Immunization Basics | CDC [WWW Document]. URL Patone, Handunnetthi, Saatci, Pan, Katikireddi, Razvi, Hunt, Mei, Dixon, Zaccardi, Khunti, Watkinson, Coupland, Doidge, Harrison, Ravanan, Sheikh, Robertson, Hippisley-Cox (b0210) 2021; 27 . Cocores, Monteith (b0045) 2016; 86 Ren, Sun, He, Zhang (b0215) 2019; 19 Godlee, Smith, Marcovitch (b0115) 2011; 342 FDA, 2005. Federal Register :: Authorization of Emergency Use of Anthrax Vaccine Adsorbed for Prevention of Inhalation Anthrax by Individuals at Heightened Risk of Exposure Due to Attack With Anthrax; Extension; Availability [WWW Document]. URL Li, Ostropolets, Makadia, Shoaibi, Rao, Sena, Martinez-Hernandez, Delmestri, Verhamme, Rijnbeek, Duarte-Salles, Suchard, Ryan, Hripcsak, Prieto-Alhambra (b0175) 2021; n1435 Shimabukuro, Nguyen, Martin, DeStefano (b0245) 2015; 33 Lee, Kang, Cho, Park, Kim, Jung, Seong, Lee (b0170) 2020; 8 Varricchio, Iskander, Destefano, Ball, Pless, Braun, Chen (b0255) 2004; 23 Shen, Mead, Beard (b0240) 2011; 52 Hawkins, Horvath, Cohen, Pace, Baum (b0140) 2021; 32 Barda, Dagan, Ben-Shlomo, Kepten, Waxman, Ohana, Hernán, Lipsitch, Kohane, Netzer, Reis, Balicer (b0010) 2021; 385 Centers for Disease Control and Prevention, 2022. Ask the Experts about Pertussis Vaccines (DTaP, Tdap) - CDC experts answer Q&As [WWW Document]. URL Witberg, Barda, Hoss, Richter, Wiessman, Aviv, Grinberg, Auster, Dagan, Balicer, Kornowski (b0260) 2021; 385 Food and Drug Authority (FDA), 2016. What is a Serious Adverse Event? | FDA [WWW Document]. URL Bellavite, P., Puliyel, J., Keele, C.E., Monitoring, U., Chandler, R., 2020. Open Peer Review Causality assessment of adverse events following immunization: the problem of multifactorial pathology [version 2; peer review: 3 approved, 1 approved with reservations]. (accessed 2.11.22). Grohskopf, L.A., Alyanak, E., Ferdinands, J.M., Broder, K.R., Blanton, L.H., Talbot, H.K., Fry, A.M., 2021. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season. MMWR. Recommendations and Reports 70, 1–32. Jefferies, Macdonald, Faust, Clarke (b0150) 2011; 7 Li, Ostropolets, Makadia, Shoaibi, Rao, Sena, Martinez-Hernandez, Delmestri, Verhamme, Rijnbeek, Duarte-Salles, Suchard, Ryan, Hripcsak, Prieto-Alhambra (b0180) 2021 World Health Organization, 2019. Causality assessment of an adverse event following immunization (AEFI) User manual for the revised WHO classification. DeStefano (b0050) 2008; 86 Kartsonaki (b0155) 2016; 22 Government of Canada, 2019. Adverse events following immunization: Canadian Immunization Guide - Canada.ca [WWW Document]. URL Lauri E. Markowitz, Eileen F. Dunne, Mona Saraiya, Herschel W. Lawson, Harrell Chesson, Elizabeth R. Unger, 2007. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) [WWW Document]. URL (accessed 9.1.22). Markowitz, Tsu, Deeks, Cubie, Wang, Vicari, Brotherton (b0190) 2012; 30 Centers for Disease Control and Prevention (CDC), 2014. Vaccine Testing and Approval Process | CDC [WWW Document]. URL Harris, Nair, Fediurek, Deeks (b0130) 2017; 35 Centers for Disease Control and Prevention, 2011. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011 [WWW Document]. URL (accessed 9.7.22). Shah, Limmer, Nwannunu, Patel, Mui, Tyring (b0235) 2019; 24 Freed, Bordley, Clark, Konrad (b0110) 1994; 93 Sathyanarayana Rao, Andrade (b0225) 2011; 53 FDA, CBER, 2020. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. FDA, 2018. CFR - Code of Federal Regulations Title 21. Fiore, A.E., Uyeki, T.M., Broder, K., Finelli, L., Euler, G.L., Singleton, J.A., Iskander, J.K., Wortley, P.M., Shay, D.K., Bresee, J.S., Cox, N.J., Centers for Disease Control and Prevention (CDC), 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59, 1–62. Fadare, J.O., Haazen, L., Lombardi, N., Crescioli, G., Bettiol, A., Tuccori, M., Rossi, M., Bonaiuti, R., Ravaldi, C., Levi, M., Mugelli, A., Ricci, S., Lippi, F., Azzari, C., Bonanni, P., Vannacci, A., 2019. Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy 10, 948. Ryan Gierke, A. Patricia Wodi, Miwako Kobayashi, 2021. Pinkbook: Pneumococcal Disease | CDC [WWW Document]. URL Campbell, Grohskopf (b0020) 2018; 32 Sathyanarayana Rao (10.1016/j.jsps.2022.10.001_b0225) 2011; 53 10.1016/j.jsps.2022.10.001_b0230 10.1016/j.jsps.2022.10.001_b0275 10.1016/j.jsps.2022.10.001_b0030 10.1016/j.jsps.2022.10.001_b0075 Godlee (10.1016/j.jsps.2022.10.001_b0115) 2011; 342 10.1016/j.jsps.2022.10.001_b0035 Li (10.1016/j.jsps.2022.10.001_b0175) 2021; n1435 Milstien (10.1016/j.jsps.2022.10.001_b0200) 2004; 25 Alguacil-Ramos (10.1016/j.jsps.2022.10.001_b0005) 2016; 135 10.1016/j.jsps.2022.10.001_b0270 10.1016/j.jsps.2022.10.001_b0070 Shah (10.1016/j.jsps.2022.10.001_b0235) 2019; 24 Freed (10.1016/j.jsps.2022.10.001_b0110) 1994; 93 Hawkins (10.1016/j.jsps.2022.10.001_b0140) 2021; 32 Shen (10.1016/j.jsps.2022.10.001_b0240) 2011; 52 Patone (10.1016/j.jsps.2022.10.001_b0210) 2021; 27 10.1016/j.jsps.2022.10.001_b0120 Cocores (10.1016/j.jsps.2022.10.001_b0045) 2016; 86 10.1016/j.jsps.2022.10.001_b0085 Zhao (10.1016/j.jsps.2022.10.001_b0280) 2011; 30 10.1016/j.jsps.2022.10.001_b0125 Nigrovic (10.1016/j.jsps.2022.10.001_b0205) 2007; 135 Campbell (10.1016/j.jsps.2022.10.001_b0020) 2018; 32 Markowitz (10.1016/j.jsps.2022.10.001_b0190) 2012; 30 10.1016/j.jsps.2022.10.001_b0080 10.1016/j.jsps.2022.10.001_b0040 DeStefano (10.1016/j.jsps.2022.10.001_b0050) 2008; 86 Ren (10.1016/j.jsps.2022.10.001_b0215) 2019; 19 Jefferies (10.1016/j.jsps.2022.10.001_b0150) 2011; 7 Hervé (10.1016/j.jsps.2022.10.001_b0145) 2019; 4 Kochhar (10.1016/j.jsps.2022.10.001_b0160) 2019; 37 10.1016/j.jsps.2022.10.001_b0055 10.1016/j.jsps.2022.10.001_b0250 10.1016/j.jsps.2022.10.001_b0135 10.1016/j.jsps.2022.10.001_b0015 Lee (10.1016/j.jsps.2022.10.001_b0170) 2020; 8 10.1016/j.jsps.2022.10.001_b0090 Witberg (10.1016/j.jsps.2022.10.001_b0260) 2021; 385 10.1016/j.jsps.2022.10.001_b0095 Kartsonaki (10.1016/j.jsps.2022.10.001_b0155) 2016; 22 10.1016/j.jsps.2022.10.001_b0105 Harris (10.1016/j.jsps.2022.10.001_b0130) 2017; 35 10.1016/j.jsps.2022.10.001_b0065 Varricchio (10.1016/j.jsps.2022.10.001_b0255) 2004; 23 10.1016/j.jsps.2022.10.001_b0220 10.1016/j.jsps.2022.10.001_b0185 10.1016/j.jsps.2022.10.001_b0025 Li (10.1016/j.jsps.2022.10.001_b0180) 2021 10.1016/j.jsps.2022.10.001_b0100 10.1016/j.jsps.2022.10.001_b0265 Lai (10.1016/j.jsps.2022.10.001_b0165) 2022; 13 Barda (10.1016/j.jsps.2022.10.001_b0010) 2021; 385 10.1016/j.jsps.2022.10.001_b0060 Mentzer (10.1016/j.jsps.2022.10.001_b0195) 2018; 23 Shimabukuro (10.1016/j.jsps.2022.10.001_b0245) 2015; 33 |
References_xml | – volume: 385 start-page: 1078 year: 2021 end-page: 1090 ident: b0010 article-title: Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting publication-title: New Engl. J. Med. contributor: fullname: Balicer – volume: 23 year: 2018 ident: b0195 article-title: Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016 publication-title: Eurosurveillance contributor: fullname: Keller-Stanislawski – volume: 53 start-page: 95 year: 2011 ident: b0225 article-title: The MMR vaccine and autism: Sensation, refutation, retraction, and fraud publication-title: Indian J. Psychiatry contributor: fullname: Andrade – volume: 23 start-page: 287 year: 2004 end-page: 294 ident: b0255 article-title: Understanding vaccine safety information from the Vaccine Adverse Event Reporting System publication-title: Pediatr. Infect. Dis. J. contributor: fullname: Chen – volume: 342 start-page: c7452 year: 2011 end-page: c ident: b0115 article-title: Wakefield’s article linking MMR vaccine and autism was fraudulent publication-title: BMJ contributor: fullname: Marcovitch – volume: 135 start-page: 1 year: 2007 end-page: 8 ident: b0205 article-title: The Lyme vaccine: a cautionary tale publication-title: Epidemiol Infect contributor: fullname: Thompson – volume: 30 start-page: 14 year: 2011 end-page: 20 ident: b0280 article-title: Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA publication-title: Vaccine contributor: fullname: Jacques-Carroll – volume: 4 start-page: 39 year: 2019 ident: b0145 article-title: The how’s and what’s of vaccine reactogenicity publication-title: npj Vaccines contributor: fullname: Tavares Da Silva – volume: 30 start-page: F139 year: 2012 end-page: F148 ident: b0190 article-title: Human Papillomavirus Vaccine Introduction – The First Five Years publication-title: Vaccine contributor: fullname: Brotherton – volume: 32 start-page: 75 year: 2018 end-page: 89 ident: b0020 article-title: Updates on Influenza Vaccination in Children publication-title: Infect. Dis. Clin. North Am. contributor: fullname: Grohskopf – volume: 33 start-page: 4398 year: 2015 end-page: 4405 ident: b0245 article-title: Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) publication-title: Vaccine contributor: fullname: DeStefano – volume: 27 start-page: 2144 year: 2021 end-page: 2153 ident: b0210 article-title: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection publication-title: Nat. Med. contributor: fullname: Hippisley-Cox – volume: 86 start-page: P1.147 year: 2016 ident: b0045 article-title: Post-Vaccination Headache Reporting Trends According to the Vaccine Adverse Events Reporting System (VAERS) (P1.147) publication-title: Neurology contributor: fullname: Monteith – volume: 86 start-page: 373 year: 2008 end-page: 380 ident: b0050 article-title: Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data publication-title: Bull World Health Organ contributor: fullname: DeStefano – volume: 35 start-page: 2600 year: 2017 end-page: 2604 ident: b0130 article-title: Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15 publication-title: Vaccine contributor: fullname: Deeks – volume: 24 start-page: 5 year: 2019 end-page: 7 ident: b0235 article-title: Shingrix for Herpes Zoster: A Review publication-title: Skin Therapy Lett contributor: fullname: Tyring – volume: 385 start-page: 2132 year: 2021 end-page: 2139 ident: b0260 article-title: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization publication-title: N. Engl. J. Med. contributor: fullname: Kornowski – volume: 13 start-page: 411 year: 2022 ident: b0165 article-title: Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong publication-title: Nat. Commun. contributor: fullname: Wong – volume: n1435 year: 2021 ident: b0175 article-title: Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study publication-title: BMJ contributor: fullname: Prieto-Alhambra – volume: 93 start-page: 747 year: 1994 end-page: 751 ident: b0110 article-title: Universal Hepatitis B Immunization of Infants: Reactions of Pediatricians and Family Physicians Over Time publication-title: Pediatrics contributor: fullname: Konrad – volume: 52 start-page: s247 year: 2011 end-page: s252 ident: b0240 article-title: The Lyme Disease Vaccine—A Public Health Perspective publication-title: Clinical Infect. Dis. contributor: fullname: Beard – volume: 37 start-page: 5796 year: 2019 end-page: 5802 ident: b0160 article-title: Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines publication-title: Vaccine contributor: fullname: Chen – volume: 22 start-page: 263 year: 2016 end-page: 270 ident: b0155 article-title: Survival analysis publication-title: Diagn Histopathol contributor: fullname: Kartsonaki – volume: 32 start-page: 783 year: 2021 end-page: 790 ident: b0140 article-title: Associations between ACA-related policies and a clinical recommendation with HPV vaccine initiation publication-title: Cancer Causes Control contributor: fullname: Baum – volume: 135 start-page: 66 year: 2016 end-page: 74 ident: b0005 article-title: Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system publication-title: Public Health contributor: fullname: Lluch-Rodrigo – volume: 25 start-page: 173 year: 2004 end-page: 189 ident: b0200 article-title: Regulation of vaccines: strengthening the science base publication-title: J Public Health Policy contributor: fullname: Milstien – volume: 19 start-page: 101 year: 2019 ident: b0215 article-title: A statistical analysis of vaccine-adverse event data publication-title: BMC Med. Inform. Decis. Mak. contributor: fullname: Zhang – volume: 8 start-page: 101 year: 2020 ident: b0170 article-title: Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barré Syndrome publication-title: Vaccines (Basel) contributor: fullname: Lee – start-page: n1435 year: 2021 ident: b0180 article-title: Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study publication-title: BMJ contributor: fullname: Prieto-Alhambra – volume: 7 start-page: 10 year: 2011 ident: b0150 article-title: Human Vaccines 13-valent pneumococcal conjugate vaccine (PCV13). Landes Bioscience 1012 publication-title: Human Vaccines contributor: fullname: Clarke – ident: 10.1016/j.jsps.2022.10.001_b0275 – volume: 86 start-page: P1.147 year: 2016 ident: 10.1016/j.jsps.2022.10.001_b0045 article-title: Post-Vaccination Headache Reporting Trends According to the Vaccine Adverse Events Reporting System (VAERS) (P1.147) publication-title: Neurology doi: 10.1212/WNL.86.16_supplement.P1.147 contributor: fullname: Cocores – volume: 37 start-page: 5796 year: 2019 ident: 10.1016/j.jsps.2022.10.001_b0160 article-title: Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2018.08.085 contributor: fullname: Kochhar – volume: 135 start-page: 1 year: 2007 ident: 10.1016/j.jsps.2022.10.001_b0205 article-title: The Lyme vaccine: a cautionary tale publication-title: Epidemiol Infect doi: 10.1017/S0950268806007096 contributor: fullname: Nigrovic – ident: 10.1016/j.jsps.2022.10.001_b0120 – ident: 10.1016/j.jsps.2022.10.001_b0030 – volume: 32 start-page: 783 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0140 article-title: Associations between ACA-related policies and a clinical recommendation with HPV vaccine initiation publication-title: Cancer Causes Control doi: 10.1007/s10552-021-01430-4 contributor: fullname: Hawkins – volume: 23 start-page: 287 year: 2004 ident: 10.1016/j.jsps.2022.10.001_b0255 article-title: Understanding vaccine safety information from the Vaccine Adverse Event Reporting System publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-200404000-00002 contributor: fullname: Varricchio – ident: 10.1016/j.jsps.2022.10.001_b0095 – ident: 10.1016/j.jsps.2022.10.001_b0265 – volume: 25 start-page: 173 year: 2004 ident: 10.1016/j.jsps.2022.10.001_b0200 article-title: Regulation of vaccines: strengthening the science base publication-title: J Public Health Policy doi: 10.1057/palgrave.jphp.3190016 contributor: fullname: Milstien – ident: 10.1016/j.jsps.2022.10.001_b0015 doi: 10.12688/f1000research.22600.2 – ident: 10.1016/j.jsps.2022.10.001_b0100 – ident: 10.1016/j.jsps.2022.10.001_b0185 doi: 10.1037/e601292007-001 – volume: 135 start-page: 66 year: 2016 ident: 10.1016/j.jsps.2022.10.001_b0005 article-title: Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system publication-title: Public Health doi: 10.1016/j.puhe.2015.11.010 contributor: fullname: Alguacil-Ramos – ident: 10.1016/j.jsps.2022.10.001_b0085 – volume: 93 start-page: 747 year: 1994 ident: 10.1016/j.jsps.2022.10.001_b0110 article-title: Universal Hepatitis B Immunization of Infants: Reactions of Pediatricians and Family Physicians Over Time publication-title: Pediatrics doi: 10.1542/peds.93.5.747 contributor: fullname: Freed – ident: 10.1016/j.jsps.2022.10.001_b0055 doi: 10.4161/hv.24657 – start-page: n1435 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0180 article-title: Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study publication-title: BMJ doi: 10.1136/bmj.n1435 contributor: fullname: Li – ident: 10.1016/j.jsps.2022.10.001_b0220 – ident: 10.1016/j.jsps.2022.10.001_b0075 – volume: 30 start-page: 14 year: 2011 ident: 10.1016/j.jsps.2022.10.001_b0280 article-title: Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA publication-title: Vaccine doi: 10.1016/j.vaccine.2011.10.076 contributor: fullname: Zhao – volume: 4 start-page: 39 year: 2019 ident: 10.1016/j.jsps.2022.10.001_b0145 article-title: The how’s and what’s of vaccine reactogenicity publication-title: npj Vaccines doi: 10.1038/s41541-019-0132-6 contributor: fullname: Hervé – ident: 10.1016/j.jsps.2022.10.001_b0105 – ident: 10.1016/j.jsps.2022.10.001_b0065 – ident: 10.1016/j.jsps.2022.10.001_b0040 – volume: 30 start-page: F139 year: 2012 ident: 10.1016/j.jsps.2022.10.001_b0190 article-title: Human Papillomavirus Vaccine Introduction – The First Five Years publication-title: Vaccine doi: 10.1016/j.vaccine.2012.05.039 contributor: fullname: Markowitz – volume: 19 start-page: 101 year: 2019 ident: 10.1016/j.jsps.2022.10.001_b0215 article-title: A statistical analysis of vaccine-adverse event data publication-title: BMC Med. Inform. Decis. Mak. doi: 10.1186/s12911-019-0818-8 contributor: fullname: Ren – volume: 342 start-page: c7452 year: 2011 ident: 10.1016/j.jsps.2022.10.001_b0115 article-title: Wakefield’s article linking MMR vaccine and autism was fraudulent publication-title: BMJ doi: 10.1136/bmj.c7452 contributor: fullname: Godlee – ident: 10.1016/j.jsps.2022.10.001_b0250 – volume: 13 start-page: 411 year: 2022 ident: 10.1016/j.jsps.2022.10.001_b0165 article-title: Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong publication-title: Nat. Commun. doi: 10.1038/s41467-022-28068-3 contributor: fullname: Lai – ident: 10.1016/j.jsps.2022.10.001_b0090 – volume: 86 start-page: 373 year: 2008 ident: 10.1016/j.jsps.2022.10.001_b0050 article-title: Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data publication-title: Bull World Health Organ doi: 10.2471/BLT.07.048025 contributor: fullname: DeStefano – volume: 27 start-page: 2144 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0210 article-title: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection publication-title: Nat. Med. doi: 10.1038/s41591-021-01556-7 contributor: fullname: Patone – volume: 35 start-page: 2600 year: 2017 ident: 10.1016/j.jsps.2022.10.001_b0130 article-title: Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15 publication-title: Vaccine doi: 10.1016/j.vaccine.2017.03.035 contributor: fullname: Harris – volume: 385 start-page: 2132 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0260 article-title: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2110737 contributor: fullname: Witberg – volume: 32 start-page: 75 year: 2018 ident: 10.1016/j.jsps.2022.10.001_b0020 article-title: Updates on Influenza Vaccination in Children publication-title: Infect. Dis. Clin. North Am. doi: 10.1016/j.idc.2017.11.005 contributor: fullname: Campbell – volume: 23 year: 2018 ident: 10.1016/j.jsps.2022.10.001_b0195 article-title: Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016 publication-title: Eurosurveillance doi: 10.2807/1560-7917.ES.2018.23.17.17-00468 contributor: fullname: Mentzer – ident: 10.1016/j.jsps.2022.10.001_b0230 – ident: 10.1016/j.jsps.2022.10.001_b0035 – ident: 10.1016/j.jsps.2022.10.001_b0060 doi: 10.3389/fphar.2019.00948 – volume: 33 start-page: 4398 year: 2015 ident: 10.1016/j.jsps.2022.10.001_b0245 article-title: Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) publication-title: Vaccine doi: 10.1016/j.vaccine.2015.07.035 contributor: fullname: Shimabukuro – volume: n1435 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0175 article-title: Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study publication-title: BMJ contributor: fullname: Li – ident: 10.1016/j.jsps.2022.10.001_b0270 – ident: 10.1016/j.jsps.2022.10.001_b0125 doi: 10.15585/mmwr.rr7005a1 – volume: 22 start-page: 263 year: 2016 ident: 10.1016/j.jsps.2022.10.001_b0155 article-title: Survival analysis publication-title: Diagn Histopathol doi: 10.1016/j.mpdhp.2016.06.005 contributor: fullname: Kartsonaki – volume: 8 start-page: 101 year: 2020 ident: 10.1016/j.jsps.2022.10.001_b0170 article-title: Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barré Syndrome publication-title: Vaccines (Basel) doi: 10.3390/vaccines8010101 contributor: fullname: Lee – ident: 10.1016/j.jsps.2022.10.001_b0070 – ident: 10.1016/j.jsps.2022.10.001_b0135 doi: 10.15585/mmwr.mm7031e1 – volume: 385 start-page: 1078 year: 2021 ident: 10.1016/j.jsps.2022.10.001_b0010 article-title: Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting publication-title: New Engl. J. Med. doi: 10.1056/NEJMoa2110475 contributor: fullname: Barda – ident: 10.1016/j.jsps.2022.10.001_b0025 – volume: 7 start-page: 10 year: 2011 ident: 10.1016/j.jsps.2022.10.001_b0150 article-title: Human Vaccines 13-valent pneumococcal conjugate vaccine (PCV13). Landes Bioscience 1012 publication-title: Human Vaccines contributor: fullname: Jefferies – volume: 52 start-page: s247 year: 2011 ident: 10.1016/j.jsps.2022.10.001_b0240 article-title: The Lyme Disease Vaccine—A Public Health Perspective publication-title: Clinical Infect. Dis. doi: 10.1093/cid/ciq115 contributor: fullname: Shen – volume: 53 start-page: 95 year: 2011 ident: 10.1016/j.jsps.2022.10.001_b0225 article-title: The MMR vaccine and autism: Sensation, refutation, retraction, and fraud publication-title: Indian J. Psychiatry doi: 10.4103/0019-5545.82529 contributor: fullname: Sathyanarayana Rao – ident: 10.1016/j.jsps.2022.10.001_b0080 – volume: 24 start-page: 5 year: 2019 ident: 10.1016/j.jsps.2022.10.001_b0235 article-title: Shingrix for Herpes Zoster: A Review publication-title: Skin Therapy Lett contributor: fullname: Shah |
SSID | ssj0025593 |
Score | 2.324616 |
Snippet | Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of collecting... Background: Vaccine adverse event reporting system (VAERS) was established in the United States (U.S.) as an early warning system with a main purpose of... |
SourceID | doaj pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1725 |
SubjectTerms | AEFI AESI COVID-19 Original Surveillance Vaccines VAERS |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwELfQXsYLgo0_hQ3dJDSBaKCOndjhbZs6VUigCkq1t8h2HK2TSKu1e-gbX4Ovt0-yuzjpFibBCy9RlDhx7Lvofuc7_46xN2izLJVTiPBQRFK5QZQZrqPES-_QoeCyoHXIL1_T0Q_5-Sw5u1Pqi3LCAj1wmLiPpuDlQGeIK0pEH3iGeCUhUO_RlBUuMIHypHWmGlcrCXS7vN6igx5Bs10mZHZdLBdE1B3HH-q8Lt4xSTVzf8cy3UeefyZQ3rFIp4_ZowZKwlEYwhP2wFc7bPukreC2ww7HgZd63YfJ7TarZR8OYXzLWL3eZbOpcRRgB0PlmZcealonCPEEtG0Q-J7h7fRo-O37u08w3HCEw7wEwWGNP8ySzpsYBJiqgAUtUP_EHq9__YawHfMpm5wOJyejqKnBEDmp4lWkpTfcqCwp-cAZZaRI08xZa7UhbBmXpkxii3epxIQX0nrPjRFWuEGmTCaesa1qXvkXDKyUTqgCPbIyltYJ4zPhiC7QaW11kfbY-1YK-SIwbeRtCtpFTjLLSWZ0DWXWY8ckqE1LYsmuL6Du5I3u5P_SnR5LWjHnDeAIQAJfNftr5wetTuQoUgqxmMrPr7CRSmtOPS167HnQkc0n4swh9uL4tOpoT2cM3TvV7Lxm_M40omAlXv6PQb9iD2koISVnj22tLq_8PgKrlX1d_0M3L0MedA priority: 102 providerName: Directory of Open Access Journals – databaseName: Elsevier Free Content dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwELYQl3KpWujP9gcZqUKtSrrr2IkdbrBahCq1QmWL9hbZjkOD1OyKXQ5762v09XgSZuxkISBx4BIljhM7mYnnczzzDSGfwGYZTKcQwaaIhLSDKNNMRYkTzsKEgokC_0P--Jke_xbfJ8lkjQzbWBh0q2zG_jCm-9G6Kek3b7M_q6r-KeNozAA_x573Dhk_kdsTg_gmh6tJVxKId5kP1oHaTeBM8PG6mM-QsjuOv3kPL9YxTp7Dv2OjHmLQ-66Ud2zT0QvyvAGV9CD0-yVZc_UmeTZsc7ltkt2TwFC93KPj24Cr-R7dpSe33NXLLVKdaYtL7VRjoua5o57giYaVBbByNDA_089nB6Nfp1_26WjFFk6nJeWMLuHTmeN-sxpBdV3QGf6q_gstXv_7T0Ng5isyPhqNh8dRk40hskLGi0gJp5mWWVKygdVSC56mmTXGKI0oMy51mcQGzmKyCceFcY5pzQ23g0zqjL8m6_W0dm8JNUJYLguYm5WxMJZrl3GLxIFWKaOKtEe-tlLIZ4FzI2-d0S5ylFmOMsMykFmPHKKgVjWRL9sXTC_P80Zhcl2wcqAyQKclYFjYA9Sb4NTQgQ4VVvRI0oo576gf3Kp6tPGdVidyECkutujaTa-gkkw9u57iPfIm6Miqi_DmAIUxuFp2tKfzDN0zdfXHc39nCvCw5O-e2N_3ZAOPgj_OB7K-uLxyHwFVLcy2_2xuACWCII8 priority: 102 providerName: Elsevier |
Title | Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact |
URI | https://dx.doi.org/10.1016/j.jsps.2022.10.001 https://www.ncbi.nlm.nih.gov/pubmed/36601511 https://www.proquest.com/docview/2761180283/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC9805973 https://doaj.org/article/ad1f089405f04508977459560e190dc4 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELe2vcALYuNfYUxGQhOIpa1jJ3Z426pOAzRUoEx9i2zHgU40rdbuoW98Db4en4Q7O-kISDzwYkVxEju5i-539t3vCHkONstgOYUImiIS0vajTDMVJU44Cw4FEwWuQ56_T88-i7eTZLJFkiYXxgftWzPtVt9m3Wr61cdWLma218SJ9Ubng0wBKJC8t022JeeNi157WUlg2mU-OwecgTpTJgR1XS4XyNEdx10f0sVa1siT9reM0t-g88_Yyd-M0eldcqdGkfQ4zHaXbLlqj9waNMXb9sjhKFBSr4_o-CbDanlED-nohqx6fY9ML7TFvXWqsTLz0lHP6ETDVgKYNRqonumLi-Phx08vX9Phhh6czkvKGV3Dv7LE43r7geqqoAtcm57BiD-__6AhE_M-GZ8Ox4OzqC6_EFkh41WkhNNMyywpWd9qqQVP08waY5RGWBmXukxiA71YXcJxYZxjWnPDbT-TOuMPyE41r9wjQo0QlssCnLEyFsZy7TJukSnQKmVUkXbIq0YK-SKQbORN9NlljjLLUWZ4DmTWIScoqM2VSJDtT8yvvuS1muS6YGVfZQBHSwCtcAQwN0Ff0AECKqzokKQRc15jjYAh4FHTfw7-rNGJHESKuyu6cvNruEimnk5P8Q55GHRkM0X4cgC7GNwtW9rTeod2D-i-J_uudf3xf9_5hNzG-YcQnH2ys7q6dk8BSK3MgV-AgPbN5ATadx_Ugf-VfgE4FSHv |
link.rule.ids | 230,315,733,786,790,870,891,2115,3525,27955,27956,45907,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4a42G8cBkwytVIaAKxpHXs3HgbVacC61RBqfYW2Y4DHTSt1vahPPE3-Hv8Eo7tpCNDQoKXKIpzc_xZ5zvxOd8BeIY2S5pyCh5uco_HquOlgiZeqLlW6FBQnpv_kIOTqP-Rvz0NT7cgrHNhbNC-khO__Dr1y8lnG1s5n6p2HSfWHg66aYKkIGbtK3AV52sQ1k565WeFTmuX2vwcdAeqXBkX1nW2mBuV7iDwbVAXbdgjK9vfMEt_0s7L0ZO_maOjGzCuO-KiUL74q6X01bdLGo__3NObcL0iqOTQNd-CLV3uwk63rgu3C_tDp3a9PiCji-StxQHZJ8MLHez1bZiMhTLL9kSYos8LTaxYFHGrFGgxiVORJs_Hh733H168Ir2N8jiZFYRRssZpuDD71coGEWVO5ua39xSf-PP7D-KSPO_A6Kg36va9qrKDp3gcLL2Ea0FFnIYF7SgRC86iKFVSykQYxhoUoggDia2mcIVmXGpNhWCSqU4ai5Tdhe1yVup7QCTnisU5-nlFwKViQqdMGRFClSQyyaMWvKyHN5s7_Y6sDmw7ywwYMgMGcwzB0ILXBgGbM432tj0wO_-UVeOSiZwWnSRFplsgH8Y9ZNChcTM1kqtc8RaENX6yisY4eoK3mvz14U9rsGU4pGbhRpR6tsKT4sgq9SWsBXsOfJtXxC-HjI7i1XEDlo0-NFsQbFZHvALX_f--8gns9EeD4-z4zcm7B3DN9MVF-jyE7eX5Sj9CvraUj-3s_AVv7kEA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLVgSMALl3ErVyOhCcSS1rETJ7yN0mpcNlVQpokXy3Yc6KBptLYP5Ym_wd_jl_DZTrplSDzspYoSp6nrY33ni4_Ph9AziFnKllMI4CMPGNe9IJMkDWLDjIaEgrDcvofc2092P7N3h_HhqVJfTrSv1SQsf0zDcvLNaSurqe42OrHuaK-fpUAKOO1WedG9iC7BnI14k6jXuVbs_XaJ26MDKUG9X8ZLu47mlXXqjqLQCbtIKyY56_5WaPqXep5VUJ4KScPr6EvTGa9E-R4uFyrUP8_4PJ6rtzfQtZqo4h3f5Ca6YMpNdKXf1IfbRFsj73q92sbjk01c8228hUcnftirW2hyILVdvsfSFn-eG-xMo7BfrYDIib2bNH5-sDP4-OnFKzxYO5DjWYEpwSuYjnN7XK9wYFnmuLKvv6fwxD-_fmO_2fM2Gg8H4_5uUFd4CDTj0SJImZFE8iwuSE9LLhlNkkwrpVJpmWtUyCKOFFy1BSwMZcoYIiVVVPcyLjN6B22Us9LcQ1gxpinPId8rIqY0lSaj2poR6jRVaZ500MtmiEXlfTxEI3A7EhYQwgLCngNAdNBri4J1S-vB7U7Mjr-KemyEzEnRSzNgvAXwYjgCJh3bdNMAyco166C4wZCo6YynKfBVk_8-_GkDOAFDahdwZGlmS2jEE-fYl9IOuusBuP6J8M8BsyNwN29Bs9WH9hUAnPMTrwF2_9x3PkGXR2-G4sPb_fcP0FXbFS_4eYg2FsdL8who20I9dhP0L1qPQ4A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccine+adverse+event+reporting+system+%28VAERS%29%3A+Evaluation+of+31+years+of+reports+and+pandemics%27+impact&rft.jtitle=Saudi+pharmaceutical+journal&rft.au=Almadani%2C+Ohoud+A&rft.au=Alshammari%2C+Thamir+M&rft.date=2022-12-01&rft.issn=1319-0164&rft.volume=30&rft.issue=12&rft.spage=1725&rft_id=info:doi/10.1016%2Fj.jsps.2022.10.001&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1319-0164&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1319-0164&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1319-0164&client=summon |